The estimated Net Worth of Gregory Sargen is at least $17.3 Million dollars as of 14 December 2023. Mr. Sargen owns over 9,612 units of Avid Bioservices Inc stock worth over $240,877 and over the last 21 years he sold CDMOP stock worth over $16,898,014. In addition, he makes $174,982 as Independent Director at Avid Bioservices Inc.
Sign up
Mr. Sargen CDMOP stock SEC Form 4 insiders trading
Gregory has made over 20 trades of the Avid Bioservices Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 9,612 units of CDMOP stock worth $240,877 on 14 December 2023.
The largest trade he's ever made was selling 165,925 units of Avid Bioservices Inc stock on 4 December 2019 worth over $9,955,500. On average, Gregory trades about 11,612 units every 73 days since 2003. As of 14 December 2023 he still owns at least 9,612 units of Avid Bioservices Inc stock.
You can see the complete history of Mr. Sargen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gregory Sargen biography
Gregory P. Sargen CPA serves as Independent Director of the Company. He was appointed to the Board of Directors pursuant to the Settlement Agreement on November 27, 2017. Mr. Sargen currently serves as Executive Vice President – Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) (“Cambrex”), a global manufacturer and provider of services to life sciences companies. Prior to his current role, Mr. Sargen served as Executive Vice President and Chief Financial Officer of Cambrex. Prior to Cambrex, Mr. Sargen served as Vice President of Finance – Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Deloitte & Touche LLP. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University. The Board of Directors concluded that Mr. Sargen should serve as a director in light of his extensive executive experience and his financial and accounting expertise with public companies in the CDMO industry.
What is the salary of Gregory Sargen?
As the Independent Director of Avid Bioservices Inc, the total compensation of Gregory Sargen at Avid Bioservices Inc is $174,982. There are 6 executives at Avid Bioservices Inc getting paid more, with Mark Ziebell having the highest compensation of $1,085,620.
How old is Gregory Sargen?
Gregory Sargen is 55, he's been the Independent Director of Avid Bioservices Inc since 2017. There are 7 older and 2 younger executives at Avid Bioservices Inc. The oldest executive at Avid Bioservices Inc is Joseph Carleone, 74, who is the Independent Non-Executive Chairman of the Board.
What's Gregory Sargen's mailing address?
Gregory's mailing address filed with the SEC is C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010.
Insiders trading at Avid Bioservices Inc
Over the last 7 years, insiders at Avid Bioservices Inc have traded over $326,500 worth of Avid Bioservices Inc stock and bought 164,445 units worth $426,401 . The most active insiders traders include Gregory Sargen, Mark R Bamforth und Richard B Hancock. On average, Avid Bioservices Inc executives and independent directors trade stock every 95 days with the average trade being worth of $895,669. The most recent stock trade was executed by Richard B Hancock on 10 September 2019, trading 10,000 units of CDMOP stock currently worth $50,900.
What does Avid Bioservices Inc's logo look like?
Complete history of Mr. Sargen stock trades at Avid Bioservices Inc, Avid Bioservices Inc und Protara Therapeutics Inc
Avid Bioservices Inc executives and stock owners
Avid Bioservices Inc executives and other stock owners filed with the SEC include:
-
Mark Ziebell,
Vice President, General Counsel, Corporate Secretary -
Daniel Hart,
Chief Financial Officer -
Richard Hancock,
Director -
Catherine Mackey,
Independent Director -
Richard Richieri,
Chief Operations Officer -
Joseph Carleone,
Independent Non-Executive Chairman of the Board -
Gregory Sargen,
Independent Director -
Patrick Walsh,
Independent Director -
Mark Bamforth,
Independent Director -
Stephanie Diaz,
Investor Relations / Corporate Communications -
Timothy Compton,
Chief Commercial Officer -
Nicholas Green,
President, Chief Executive Officer, Director -
Roger J. Lias,
President & CEO -
Joel Mc Comb,
Director